Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Renal cell carcinoma (RCC) has undergone a profound therapeutic transformation over the past two decades. The management of metastatic clear-cell RCC has moved from cytokine-based approaches to vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), immune checkpoint inhibitors, and combinations of immunotherapy and targeted therapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
